Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
Our AI ranks Marpai, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Marpai, Inc. is a small-cap company with a market capitalization of $85M. It ranks number 8 by market capitalization among the 13 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
For MRAI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -36.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -21.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MRAI included.
Follow MRAI free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
| Metric | MRAI | Rank |
|---|---|---|
| Market Cap | $85M | 8/13 |
| EPS | $-0.85 | – |
| Revenue/Share | $0.62 | – |
| Metric | MRAI | Rank |
|---|---|---|
| ROA | -178.4% | 9/9 |
| ROIC | 96.7% | 1/8 |
| Gross Margin | 25.9% | 5/6 |
| Operating Margin | -81.8% | 7/9 |
| Net Margin | -101.5% | 9/10 |
| EBT Margin | -101.5% | 8/10 |
| Metric | MRAI | Rank |
|---|---|---|
| Current Ratio | 0.38x | 10/11 |
| Interest Coverage | -190.7x | 11/12 |
| Working Capital | -$15M | 11/11 |
| Metric | MRAI | Rank |
|---|---|---|
| Operating Cash Flow | -$9M | 8/10 |
| Metric | MRAI | Rank |
|---|---|---|
| Asset Turnover | 1.76x | 3/9 |
| Receivables Turnover | 16.4x | 1/9 |
| Days Sales Outstanding | 22 days | 9/9 |
| Payables Period | 171 days | 2/5 |
| Metric | MRAI | Rank |
|---|---|---|
| Total Revenue | $17M | 8/10 |
| Operating Income | -$14M | 6/9 |
| Net Income | -$17M | 8/10 |
| R&D Expense | $10K | 5/5 |
| SG&A Expense | $17M | 5/5 |
| Cost of Goods Sold | $12M | 4/7 |
| Metric | MRAI | Rank |
|---|---|---|
| Shares Outstanding | 27M | – |
| Total Current Assets | $9M | |
| Cash & Short-term Investments | $140K | |
| Accounts Receivable | $1M | |
| Total Liabilities | $48M | |
| Short-term Debt | $18M |
Companies classified under the same SEC industry code as Marpai, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| MRAI Marpai, Inc. | ▲ | $85M |
| FMS Fresenius Medical Care Ag | ▼ | $12.85B |
| DVA Davita Inc. | ▶ | $11.95B |
| SHC Sotera Health Co | ▼ | $5.16B |
| PGNY Progyny, Inc. | ▼ | $2.11B |
| AGL Agilon Health, Inc. | ▲ | $1.43B |
| VMD Viemed Healthcare, Inc. | ▼ | $371M |
| PARK Park Dental Partners, Inc. | ▲ | $91M |
| CCEL Cryo Cell International Inc | ▲ | $29M |
| PFHO Pacific Health Care Organization Inc | ▶ | $12M |
| MGRX Mangoceuticals, Inc. | ▲ | $7M |
| NIVF Newgenivf Group Ltd | ▼ | $2M |
| BRTX Biorestorative Therapies, Inc. | ▼ | $2M |
Marpai, Inc. (NASDAQ:MRAI) shareholders have had their patience rewarded with a 116% share price jump in the last month. Looking back a bit further, it's encouraging to see the stock is up 39% in the ...
Edmundo Gonzalez is the CEO of Marpai Inc. He has a proven track record in the industry and has been instrumental in the growth and success of the company. His recent purchase of Marpai Inc shares ...
Marpai, Inc. (NASDAQ:MRAI) Q4 2024 Earnings Call Transcript March 27, 2025 Operator: Good morning, and welcome to the Marpai Fourth Quarter and Full-Year 2024 Earnings Conference Call. Marpai, Inc.
Our AI ranks Marpai, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For MRAI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -36.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -21.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Marpai, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
13 issuers in our coverage, MRAI included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Fresenius Medical Care Ag (FMS), Davita Inc. (DVA), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.